WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio.

Through an agreement with Linepharma, WomanCare Global will provide sales, marketing, provider training and distribution of mifepristone in seven European and seven African countries. Linepharma’s mifepristone is labeled for use as a single 200mg tablet of mifepristone to perform medical abortion in conjunction with a prostaglandin, in compliance with the World Health Organization’s recommendation.

Linepharma’s mifepristone is manufactured in Europe and is currently approved in five E.U. countries. The planned distribution of mifepristone by WomanCare Global in 14 countries will ensure that close to 55 million women will have another safe, quality product to manage their reproductive health.

Please read the entire press release at http://ow.ly/8W2Wz